Status:
COMPLETED
Early Identification of Candida in Intra-abdominal Candidiasis
Lead Sponsor:
Central Hospital, Nancy, France
Collaborating Sponsors:
SYMCEL
Conditions:
Candida Sepsis
Candidiasis, Invasive
Eligibility:
All Genders
Brief Summary
Intra-abdominal candidiasis remains the first origin of invasive candidiasis in critically ill patients with a mortality up to 60%. This high mortality is partly related to delay of anti-fungal treatm...
Detailed Description
The high mortality rate of patients with intra-abdominal candidiasis infection is partly related to delay in anti-fungal treatment. The gold standard method for Candida detection remains the yeast cul...
Eligibility Criteria
Inclusion
- The criteria belong to the pBDG2 study (Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients).
- adult
- Covered by health insurance
- Admitted in ICU with intra-abdominal infection requiring abdominal surgery or percutaneous drainage
Exclusion
- Pregnant or lactating woman
- Patient deprived of liberty after administration of juridical decision
- Patient under psychiatric care
Key Trial Info
Start Date :
February 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 22 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05264571
Start Date
February 17 2022
End Date
June 22 2023
Last Update
July 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Hospital
Vandœuvre-lès-Nancy, France, 54500